Chandrima Sanyal February 8, 2026 at 10:31 PM Cathie Wood’s ARK Invest is reshuffling its crypto exposure across flagship ETFs, snapping up shares of
Latest News
The Best Quantum Computing Stocks to Buy With $3,000
Quantum computing stocks are on sale right now. Quantum computing has taken a step back in popularity over the past few months. After peaking
What Is Crypto Options Trading and How Does It Work?
Learn how crypto options trading works, strategies, pricing, and risk management for BTC, ETH, and other digital assets.
Laid Off? Here's How ETFs Fit Into Financial Planning After Job Loss
Chandrima Sanyal February 9, 2026 at 7:31 PM A recent surge in U.S. job lay-offs – from technology to transportation, healthcare to media –
XRP ETFs See $6.31 Million in Daily Inflows as XRPC, GXRP, and XRPZ Excel
TLDR Table of Contents XRP ETFs total daily net inflows of $6.31M with a cumulative net inflow of $1.23B as of February 9. The
The Fed’s Big 2026 Debate: What’s a Normal Level for Rates?
Key Takeaways The Federal Reserve’s decision on whether to cut interest rates again depends heavily on the uncertain “neutral rate,” the level at which
Bitcoin rebound has hit a wall at $71,000 with sentiment at most fearful since 2022
Bitcoin’s BTC$69,817.08 rebound from last week’s selloff is already running into a wall. After briefly sliding into the low-$60,000s in a capitulation-style move last
South Korean crypto exchange races to recover $40bn of bitcoin sent to customers by mistake
South Korea’s second-largest cryptocurrency exchange is scrambling to recover more than $40bn of cryptocurrency after accidentally crediting customers with 620,000 bitcoins during a promotional
Ethereum and AI: Vitalik Buterin’s Vision for Privacy, Economic Layer, and Governance
TLDR Table of Contents Vitalik Buterin proposes Ethereum as a key tool for privacy-preserving AI interactions and trust-minimized AI systems. He advocates for local
Why Edgewise Therapeutics Stock Crushed the Market on Monday
The company will publish very encouraging results from a clinical trial soon, one pundit believes. As investors, we should never underestimate the power of